Immunome (IMNM) Return on Sales (2023 - 2026)

Immunome's Return on Sales history runs 4 years deep, the most recent figure standing at 1.22% for Q1 2026.

• Quarterly Return on Sales fell 107.0% year-over-year to 1.22% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 1.22% (down 92.0% YoY) and the FY2025 annual result came in at 0.58%, down 13.0% from the prior year.
• Return on Sales was 1.22% for Q1 2026 at Immunome, down from 0.42% in the prior quarter.
• Across five years, Return on Sales topped out at 0.02% in Q1 2023 and bottomed at 1.29% in Q1 2024.
• A 4-year average of 0.38% and a median of 0.3% in 2024 frame the typical range for Return on Sales.
• Annual changes were most pronounced in 2024 — Return on Sales tumbled 127 bps — and 2025, when it surged 113 bps.
• Immunome's Return on Sales stood at 0.25% in 2023, then slipped by 23 bps to 0.3% in 2024, then plunged by 37 bps to 0.42% in 2025, then tumbled by 192 bps to 1.22% in 2026.
• Business Quant data shows IMNM's Return on Sales at 1.22% in Q1 2026, 0.42% in Q4 2025, and 0.31% in Q3 2025.